These data establish that GIV confers resistance to clinically used drugs for ER+ breast cancer and suggest that upregulation of GIV in cancer cells in close contact with MSCs may permit disseminated ER+ breast cancer cells to survive therapy in bone marrow. This evidence concerns the gene CCDC88A and cancer.